Does lowering lipoprotein(a) have an impact on cardiovascular risk?

+Practice

In print

Heartbeat

Does lowering lipoprotein(a) have an impact on cardiovascular risk?

February 2025

Chris Ellis

Wednesday 29 January 2025, 12:30 AM

ECG supplied

Consultant cardiologist Chris Ellis looks at what we know and what we don’t know about lipoproteins, cardiovascular risk and optimal management

Key points, Lipoprotein(a) is a circulating lipoprotein that predicts atherosclerotic disease, cardiovascular events and aortic valve stenosis. New drugs can lo, Pract Green w Pale Yellow

Research

References

1. Katsiki N, Vrablik M, Banach M, et al. Inclisiran, low-density lipoprotein cholesterol and lipoprotein (a). Pharmaceuticals (Basel) 2023;16(4):577.

2. O’Riordan M. Two Lp(a)-Lowering Therapies Clear Bar in KRAKEN and ALPACAR-360. TCTMD, 18 November 2024.

3. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020;41(1):111–88.

How to Treat

+How to treat

For older people and frail people, the long-term benefit of medicines reduces and the potential for harm from adverse effects increases. When the benefit–risk balance changes in this way, medicine review and optimisation are important to simplify the therapeutic regimen, reduce inappropriate medicines and minimise risks. In this article, pharmacist prescriber Linda Bryant uses two case studies to illustrate important considerations during medicine reviews

Wednesday 28 May 2025, 12:50 AM